



Pergamon

Bioorganic & Medicinal Chemistry Letters 12 (2002) 1133–1134

BIOORGANIC &
MEDICINAL
CHEMISTRY
LETTERS

Corrigendum

Corrigendum to “Synthesis and Anti-Angiogenic Activity of 6-(1,2,4-Thiadiazol-5-yl)-3-amino Pyridazine Derivatives” [Bioorg. Med. Chem. Lett. 12 (2002) 589][†]

Jean-Pierre Bongartz,^{a,*} Raymond Stokbroekx,^a Marcel Van der Aa,^a Marcel Luyckx,^a Marc Willems,^a Marc Ceusters,^a Lieven Meerpoel,^a Gerda Smets,^a Tine Jansen,^a Walter Wouters,^a Charlie Bowden,^a Lisa Valletta,^b Mark Herb,^b Rose Tominovich^b and Robert Tuman^b

^a*Janssen Research Foundation, Turnhoutseweg 30, B-2340 Beerse, Belgium*









^b*RW Johnson Pharmaceutical Research Institute, Drug Discovery, Welsh and McKean Roads, PO Box 776, Spring House, PA 19477-0776, USA*

Regrettably, Table 1 of the above article was incorrect. The corrected table is published on the following page.

*Corresponding author. Fax +32-14-60-53-44; e-mail: jpbongart@janbe.jnj.com

[†]PII of original article: S0960-894X(01)00805-8

Table 1. Rat aortic ring microvessel growth inhibition, eye toxicity and 3LL-Lewis Lung tumor mets formation inhibition results for

No.	R ₁	R ₂	R ₃	X	Aortic ring IC ₅₀ (nM)	Eye toxicity	% Inhibition (mpk/b.i.d.)
1	CH ₃			3-Cl	0.6	Yes	NT
2	CH ₃		II	3-CF ₃	5	No	NT
3	CH ₃		II	3-CF ₃	10	No	NT
4	CH ₃		II	3-CF ₃	> 100	No	NT
5	CH ₃		II	3-CF ₃	> 100	NT	NT
6	H	I	II	3-CF ₃	70	No	NT
7	CH ₃ CH ₂	I	II	3-CF ₃	8	No	NT
8	NH ₂	I	II	3-CF ₃	20	No	NT
9	NHCH ₃	I	II	3-CF ₃	0.4	No	39% (15)
10	N(CH ₃) ₂	I	II	3-CF ₃	6	No	NT
11	CH ₃	I	II	3-CF ₃	0.3	Yes	NT
12	CH ₃	I	II	3-F	6	NT	NT
13	CH ₃	I	II	3-CN	3	NT	NT
14	CH ₃	I	II	3-NO ₂	3	Yes	NT
15	CH ₃	I	II	3-NH ₂	> 100	NT	NT
16	CH ₃	I	II	3-OCH ₃	7	NT	NT
17	CH ₃	I	II	2-CF ₃	0.2	Yes	NT
18	CH ₃	I	II	4-CF ₃	12	NT	NT
19	CH ₃	I	II	3,5-CF ₃	< 0.1	Yes	NT
20	CH ₃	I	II	3,5-Cl	< 0.1	Yes	NT
21	H	I	II	3,5-CF ₃	< 1	No	24% (15)
22	H	I		3-CF ₃	0.7	No	42% (15)
23	H	I		3-CF ₃	0.3	No	54% (15)
24	N(CH ₃) ₂	I	III	3-CF ₃	< 1	Very weak	25% (15)
25	N(CH ₃) ₂	I	II	3,5-CF ₃	0.1	No	13% (15)
26	NHCH ₃	I	II	3-CF ₃	0.4	No	39% (15)

NT, not tested.